936727-93-4

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-(trifluoromethoxy)phenyl)cyclopropanecarboxylic acid is used as a building block for the synthesis of various drugs and biologically active molecules. Its unique structure and properties make it a valuable component in the development of new medications and therapeutic agents.
The specific properties and potential applications of 1-(4-(trifluoromethoxy)phenyl)cyclopropanecarboxylic acid are still being researched and explored. However, its potential in drug discovery and development is significant. Chemists and researchers need to understand its structure, reactivity, and potential biological effects to fully harness its potential in creating innovative and effective treatments for various diseases and conditions.

InChI:InChI=1/C11H9F3O3/c12-11(13,14)17-8-3-1-7(2-4-8)10(5-6-10)9(15)16/h1-4H,5-6H2,(H,15,16)

Upstream product

• 173859-39-7 1-((4-trifluoromethoxy)phenyl)cyclopropanecarbonitrile 
• 49561-96-8 (4-trifluoromethoxy-phenyl)-acetonitrile 
• 952444-05-2 1-(4-(trifluoromethoxy)phenyl)cyclopropanecarbamide 

Downstream Products

• 1239707-78-8 (S)-3-(4-bromophenyl)-2-(1-(4-(trifluoromethoxy)phenyl)cyclopropanecarboxamido)propanoic acid 
• 1239707-77-7 (S)-ethyl 3-(4-bromophenyl)-2-(1-(4-(trifluoromethoxy)phenyl)cyclopropanecarboxamido)propanoate 
• 1373527-99-1 C₂₂H₂₀Cl₂F₃NO₄ 
• 1373527-88-8 (S)-3-(2,4-dichlorophenyl)-2-(1-(4-(trifluoromethoxy)phenyl)cyclopropanecarboxamido)propanoic acid 
• 1239894-07-5 N-{(1S)-2-(3-amino-8-azabicyclo[3.2.1]oct-8-yl)-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl}-1-{4-[(trifluoromethyl)oxy]phenyl}cyclopropanecarboxamide 
• 952443-57-1 (3R,4R)-(3-(4,6-dimethylquinolin-2-ylamino)-4-hydroxypyrrolidin-1-yl)-(1-(4-trifluoromethoxyphenyl)cyclopropionyl)methanone 

Relevant academic research and scientific papers

Discovery and characterization of an inhibitor of glucosylceramide synthase

Targeting glycosphingolipid synthesis has emerged as a novel approach for treating metabolic diseases. 32 (EXEL-0346) represents a new class of glucosylceramide synthase (GCS) inhibitors. This report details the elaboration of hit 8 with the goal of achieving and maintaining maximum GCS inhibition in vivo. 32 inhibited GCS with an IC50 of 2 nM and achieved maximum hepatic GCS inhibition after four or five daily doses in rodents. Robust improvements in glucose tolerance in DIO mice and ZDF rats were observed after 2 weeks of q.d. dosing. Four weeks of dosing resulted in decreased plasma triglycerides and reduced hepatic fat deposition. Thus, 32 provides insight into the amount of metabolic regulation that can be restored following achievement of maximal target knockdown.

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.

Methods and Compositions for Selectin Inhibition

The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

AMINOPYRROLIDINE COMPOUND

Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC4 receptor antagonistic effect.